13 #AHA24 ScientificSessions.org designed for growing children. This effort has led to a novel growthaccommodating heart valve that is now in clinical trials. Del Nido was born in Santiago, Chile, and immigrated to the United States at age 10. He attended undergraduate and medical school at the University of WisconsinMadison. He completed a general surgery internship and residency at Boston University and entered cardiothoracic residency at the University of Toronto. Before starting his clinical training, he spent a year in the laboratory at the Banting Institute of the University of Toronto, where he began his work on myocardial preservation. That research focus continued through his residency and early career in congenital cardiac surgery. Del Nido spent an additional year as a clinical fellow at the Hospital for Sick Children in Toronto. He started his career at the University of Illinois Chicago then moved to the University of Pittsburgh, where he developed a solution to preserve the heart during prolonged heart surgery. This solution, now known as “del Nido cardioplegia,” is one of the most widely used cardioplegia formulations around the world. In 1994, del Nido joined the faculty at Boston Children’s Hospital and Harvard Medical School. He rose to the rank of professor of surgery and in 2004, he was named William E. Ladd Professor of Child Surgery at Harvard Medical School and cardiac surgeonin-chief at Boston Children’s. Del Nido has received NIH funding throughout his career. He has over 500 peer-reviewed publications and more than 50 awarded and pending patents. Jiang He, MD, PhD, MSc, FAHA Tulane University New Orleans Jiang He is an internationally renowned scientist in epidemiological, clinical and translational research in cardiometabolic diseases. He has been principal investigator and co-investigator for more than 50 major NIH research awards and has been an author of more than 750 scientific articles published in top-tier biomedical journals. He has led landmark studies that have documented: • Cardiovascular disease and cancer as the leading causes of death, with hypertension and cigarette smoking as the primary preventable risk factors for premature death in China. • The rapid acceleration of the global burden of obesity and diabetes, accompanied by large global disparities in hypertension. • The increased risk of cardiovascular disease and allcause mortality associated with high sodium intake in people with obesity or chronic kidney disease. • The safety of early antihypertensive treatment in people with acute ischemic stroke. • The effectiveness of an intervention led by community health workers to lower blood pressure, improve hypertension control and significantly reduce cardiovascular events, all-cause dementia and total mortality. These study findings contribute to cardiometabolic disease prevention in resourceconstrained populations globally. He is a dedicated educator who has mentored more than 100 master’s students and more than 50 doctoral students and postdoctoral fellows. He has also mentored over 20 junior faculty investigators, many of whom have developed successful research careers and become leaders in their fields. He has received numerous awards from local, national and international academic institutions and professional societies, including the Distinguished Alumnus Award from Johns Hopkins University, Research Hall of Fame induction from Tulane University, the Detlev Ganten Excellence Award in Hypertension and Global Health Implementation from the World Hypertension League, and the Abraham Lilienfeld Award from the American College of Epidemiology. See AWARDS, page 14 Please join us for a special presentation on data generation and select methodologies that can help inform clinical practice MOVING BEYOND CLINICAL TRIALS: UNDERSTANDING REAL-WORLD EVIDENCE IN VENOUS THROMBOEMBOLISM (VTE) November 17, 2024 9:30-10:30 am CST Learning Studio II Please book your calendar to join us: FACULTY PRESENTERS: TOPICS OF DISCUSSION: • The use of randomized controlled trials (RCTs) and real-world evidence (RWE) • Select methodologies for conducting and analyzing real-world studies • Examples of real-world observational studies of select anticoagulants in patients with VTE This event is not part of the official Scientific Sessions 2024 as planned by the American Heart Association Committee on Scientific Sessions Program © 2024 Bristol-Myers Squibb Company CV-US-2400256 09/2024 Steven B. Deitelzweig MD, MMM, FACC, SFHM, FACP, RVT System Chairman, Hospital Medicine Medical Director of Regional Business Development, Ochsner Health Professor of Medicine, University of Queensland and Ochsner Clinical School W. Frank Peacock MD, FACEP, FACC, FESC Professor and Vice Chair of Research at the Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine Paid Advertisement CV-US-2400256_AHA_Junior-Pg_Journal_Ad_R02.indd 1 10/9/24 10:37 AM
RkJQdWJsaXNoZXIy MjI2NjI=